IL2 and systemic lupus erythematosus: Zhao et al. also demonstrated in the non-randomized clinical trials on patients with severe refractory SLE that require large doses of prednisone or cytotoxic drugs, that combination with low-dose IL2 may not only alleviate the disease effectively but also decrease the dose of prednisone and cytotoxic drugs required to induce and maintain remission and ultimately be beneficial to patients in terms of decreased incidence of treatment-associated adverse effects [16].